A once-daily pill that reprograms your gut bacteria could deliver the fat-burning power of ketosis — no carb-cutting required
The ketogenic diet has one of the most devoted followings in modern nutrition — and one of the highest dropout rates. The science behind it is compelling: force the body to run on fat instead of sugar, and the weight comes off fast. The lifestyle required to get there, however, is another matter entirely. Giving up bread, rice, fruit, and pasta indefinitely is a commitment that the vast majority of people simply cannot — or will not — keep.
That tension between keto’s remarkable results and its brutal demands has long represented one of medicine’s most tantalizing unsolved problems. Now a California-based biotech company believes it may finally have an answer — not in the form of another fad diet or celebrity-endorsed meal plan, but in a small, swallowable capsule taken once a day.
The pill is called BL-001. And if the early data holds up, it could change the way the world thinks about weight loss entirely.
While experimental therapies like BL-001 continue to advance through clinical trials, those seeking an effective weight management solution today need not wait. PhenQ has established itself as one of the most credible over-the-counter options on the market, building a strong track record over more than a decade of consumer use.
Its multi-action formula — combining appetite suppression, thermogenic fat burning, and metabolic support through evidence-backed ingredients including α-Lacys Reset, capsimax powder, and chromium picolinate — addresses multiple drivers of weight gain within a single daily capsule.
Available without a prescription, PhenQ represents a practical, proven option for individuals looking to take meaningful steps toward weight loss right now.
Rethinking Weight Loss From the Gut Up
Content
Bloom Science, the San Diego startup behind BL-001, is taking a fundamentally different approach to obesity treatment than the drugs currently dominating the market. Rather than suppressing hunger signals in the brain — the mechanism behind blockbuster GLP-1 injectable drugs like Ozempic and Wegovy — Bloom Science is going straight to the gut.
BL-001 is what scientists call a Live Biotherapeutic Product, or LBP: a carefully formulated preparation of living bacterial strains that, once swallowed, colonize the digestive tract and begin reshaping the gut microbiome. The goal is to recreate, at a microbial level, the metabolic environment that the ketogenic diet produces through weeks of strict carbohydrate restriction.
When the body is deprived of carbohydrates, it runs out of glucose to burn and begins breaking down fat reserves into molecules called ketone bodies — an alternative energy source that gives the keto diet its name. Bloom Science’s central argument is that specific gut bacteria act as key facilitators of this process, and that by reintroducing those strains in pharmaceutical-grade form, the body can be nudged into fat-burning mode without any dietary changes at all.
What the First Human Trial on BL-001 Revealed
Bloom Science moved BL-001 into its first human trial in late 2024, with results announced in March 2025. The study was small but rigorously designed: 32 adults across a range of body weights were randomly assigned to receive either BL-001 or a placebo once daily for 28 days. It was fully double-blinded — meaning no one involved, not the participants and not the researchers administering the trial, knew who was receiving the active pill.
When the data was unblinded, the results stood out. Overweight participants in the BL-001 group lost an average of 2.3% of their total body weight over the four-week period — a statistically robust finding, with a p-value of 0.0007 that makes random chance an extremely unlikely explanation. One participant lost nearly 5% of their body weight within the treatment window alone.
But the most scientifically intriguing finding came after the trial ended. When researchers checked back two weeks after participants took their final dose, 80% of those who had lost weight had kept it off. More remarkably still, every overweight participant in the highest-dose group continued to lose weight even after stopping — eventually averaging a total reduction of 3.4% from their starting weight.
Lab analysis confirmed what the scale was showing. Participants in the BL-001 group had measurably elevated urinary ketones — direct chemical evidence that their bodies had shifted into a ketogenic fat-burning state — along with reduced appetite and changes in key metabolic hormones. Crucially, no serious safety concerns were identified at any point in the trial.
Scaling Up: BL-001 The Phase 1b Trial
On the back of those encouraging findings, Bloom Science dosed its first patient in a Phase 1b trial in February 2026. This expanded study will enroll 48 adults classified as clinically obese — a more targeted population than the Phase 1 cohort — and will run for 12 weeks, giving researchers three times as long to observe BL-001’s effects on body weight, metabolic markers, and tolerability.
The trial is being conducted at sites in Australia and represents a significant step up in both ambition and scientific rigor. Where Phase 1 was primarily about establishing that the pill was safe in humans, Phase 1b is designed to build a clearer picture of how meaningful — and how durable — the weight loss effects really are across a longer timeframe.
Dr. Christopher Reyes, the biophysicist who serves as Bloom Science’s CEO, is candid about why the company believes BL-001 occupies a unique space in the weight loss landscape. “Millions of patients remain untreated because existing therapies don’t align with their preferences,” he has said. “BL-001 is designed to change that — delivering the metabolic benefits of the ketogenic diet in a daily oral capsule, without injections or dietary restriction”.
That pitch speaks directly to a very real gap in the market. For all the transformative impact that GLP-1 injectable drugs have had on obesity treatment, a significant proportion of patients cannot tolerate their gastrointestinal side effects, while others are deterred by the prospect of weekly self-injection. Bloom Science’s own market research found robust interest in an orally administered, microbiome-based alternative — even among people who had previously tried GLP-1 therapies.
A Bridge for Those Who Can’t Wait
For people seeking an effective weight management option available right now, while experimental therapies like BL-001 work their way through clinical trials, PhenQ has quietly established itself as one of the most trusted over-the-counter choices on the market. Available without a prescription and backed by over a decade of consumer use, PhenQ takes a multi-action approach to weight loss — combining appetite suppression, fat-burning support, and energy enhancement in a single daily formula. Its blend of ingredients, including α-Lacys Reset, capsimax powder, and chromium picolinate, is designed to address multiple contributors to weight gain simultaneously, making it a practical and popular option for people who want to take meaningful action today, rather than waiting for the next generation of clinical breakthroughs to arrive.
The Epilepsy Angle
One of the more unexpected dimensions of BL-001’s development is its potential relevance to a condition far removed from obesity: Dravet syndrome, a rare and devastating form of genetic epilepsy that typically appears in the first year of life and causes frequent, often prolonged seizures that respond poorly to standard medications.
The connection to keto is not coincidental. The ketogenic diet has been used as a therapeutic tool in drug-resistant epilepsy for nearly a century, with strong evidence that it can meaningfully reduce seizure frequency in a subset of patients — including those with Dravet syndrome. The mechanism is partly metabolic and partly neurological: ketone bodies appear to stabilize electrical activity in the brain, while certain gut bacteria influence the GABA neurotransmitter system, which plays a central role in preventing the runaway neural firing that causes seizures.
Bloom Science’s preclinical data suggests BL-001 can replicate both of these effects, and the company has indicated it plans to initiate Phase 2 trials targeting Dravet syndrome alongside the ongoing obesity work in 2026. For families managing this condition — for whom sustaining a strict ketogenic diet in a young child is a daily struggle — the prospect of a once-daily pill achieving the same outcome would be, in the most literal sense, life-changing.
The Long Road Ahead
None of this means BL-001 will be on pharmacy shelves anytime soon. Phase 1 and 1b trials are the very beginning of a regulatory pathway that typically spans many years and multiple rounds of large-scale testing. The current data, while scientifically compelling, comes from a small number of participants over a short period — and weight loss research has a long history of early promise that fails to survive contact with larger, longer, more diverse trials.
For BL-001 to reach patients, Bloom Science will need to demonstrate not only that the pill continues to produce statistically significant weight loss across hundreds of participants over months — but also that the results are safe, durable, and clinically meaningful enough to satisfy regulators at the FDA and equivalent bodies in other countries.
What the current data does establish, however, is that the underlying concept is scientifically credible. The gut microbiome’s role in metabolic health has become one of the most intensively researched areas of medicine over the past decade, and the idea that targeted bacterial strains can shift the body’s energy metabolism is no longer fringe science — it is an active and well-funded frontier.
If BL-001 continues to perform, it would represent something the weight loss industry has been chasing for generations: a treatment that works with the body’s own biology, requires no injections, imposes no dietary suffering, and leaves patients healthier — not just lighter. The keto diet has always offered that tantalising promise to those willing to pay its steep lifestyle price. BL-001 is a bet that the price, one day soon, need not be so high.
BL-001 is an investigational therapy and has not been approved by the FDA or any regulatory authority. This article is for informational purposes only and does not constitute medical advice. Individual weight loss results vary.
Be the first to comment